Stay updated with breaking news from Develop Drugs. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Akero Therapeutics (AKRO) said its drug efruxifermin ((EFX)) improved liver fibrosis without the worsening of liver disease, meeting the main goal of a Phase 2b study.The...
Biophytis (BPTS) said its drug Sarconeos was better at reducing the risk of respiratory failure or early death in patients with COVID-19,compared to placebo.The phase 2-3 study,...
AstraZeneca (AZN) and Ionis Pharmaceuticals (IONS) presented detailed results from a 35-week interim analysis of a phase 3 trial of eplontersen, which had met its main goal, in...
BridgeBio Pharma's stock fell at the end of 2021 on some disappointing trial results. Read whether late-stage candidates and collaboration deals make BBIO a Buy.
72% technical buy signal. 15 new highs and up 59.18% in the last month. Price targets from $23 to $53. Click here to read more about FMTX stock.